PharmaRoth Labs Completes First Shipment With Mexican Distributor
2013年8月20日 - 5:15AM
Marketwired
PharmaRoth Labs, Inc. (OTC Pink: ROTH), the exclusive producer and
marketer of Sucanon®, an oral Type-II Diabetes treatment, announced
that it has shipped the first order from their new Mexican
distributor Marcas de Renombre.
"We are very excited to begin fulfilling orders for Sucanon® so
soon after establishing our agreement with MDR," said Luis Lopez,
CEO of PharmaRoth. "With Mexico having, unfortunately, been named
the most obese nation in the world, Type II Diabetes is and will
continue to be a major health problem. The Mexican market is a very
large and important one for the company. We look forward to
aggressively marketing Sucanon® in Mexico with our new
partners."
About Sucanon® Sucanon® is a dietary
supplement containing natural ingredients. In certain ex-US
countries, it is one of only three approved drugs in the
multi-billion dollar market for a class of diabetic medications
called "insulin sensitizers." Pre-clinical and clinical studies
conducted ex-US have shown that Sucanon® and other insulin
sensitizers lower a patient's blood sugar by increasing the muscle,
fat and liver's sensitivity to the body's own naturally produced
insulin. Sucanon® has been approved for prescription sale in China
and Peru. Sucanon® is also approved as an OTC treatment for Type-II
diabetes by regulatory authorities in Mexico. Sucanon® will be
marketed as a dietary supplement in the US.
For further information regarding Sucanon®, please visit
PharmaRoth Labs, Inc. website at www.pharmaroth.com
About PharmaRoth Labs Inc. PharmaRoth
Labs, Inc. (OTC Pink: ROTH) is focused on diabetes prevention and
treatments. The Company holds the intellectual property and all
exclusive world-wide rights related to the production, marketing,
and distribution of Sucanon®, an oral treatment for Type-II
diabetes. Sucanon® is a member of a class of diabetic medications
called insulin sensitizers. Insulin sensitizers lower blood sugar
by increasing the muscle, fat and liver's sensitivity to insulin.
Insulin sensitizers are blood sugar normalizing or euglycemic drugs
that help return the blood sugar to the normal range without the
risk of low blood sugars. PharmaRoth's strategy is to increase
awareness, acceptance, and distribution of Sucanon® globally.
Forward Looking Statements: Statements in
this document contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. These
statements are based on many assumptions and estimates and are not
guarantees of future performance. These statements may involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of PharmaRoth
Labs, Inc. to be materially different from future results,
performance or achievements expressed or implied by such
forward-looking statements. PharmaRoth Labs, Inc. assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Our actual results may differ materially
from the results anticipated in these forward-looking statements
due to a variety of factors. There may be other factors not
mentioned above that may cause actual results to differ materially
from those projected in any forward-looking statement. We assume no
obligation to update any forward-looking statements as a result of
new information, future events or developments, except as required
by applicable securities laws.
For investor relations contact: Michael Irving Paramount
Advisors, LLC (407) 878-5462
PharmaRoth Labs (CE) (USOTC:ROTH)
過去 株価チャート
から 9 2024 まで 10 2024
PharmaRoth Labs (CE) (USOTC:ROTH)
過去 株価チャート
から 10 2023 まで 10 2024